A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Seagen Inc.
Pliant Therapeutics, Inc.
Merck Sharp & Dohme LLC
National Institutes of Health Clinical Center (CC)
AstraZeneca
Eikon Therapeutics
Genmab
M.D. Anderson Cancer Center
Eisai Inc.
Merck Sharp & Dohme LLC
PMV Pharmaceuticals, Inc
Mayo Clinic
Sutro Biopharma, Inc.
National Institutes of Health Clinical Center (CC)
University of Miami
Tizona Therapeutics, Inc
Ohio State University Comprehensive Cancer Center
M.D. Anderson Cancer Center
Dana-Farber Cancer Institute
University of Oklahoma
IDEAYA Biosciences
Merck Sharp & Dohme LLC
Sichuan Baili Pharmaceutical Co., Ltd.
Eli Lilly and Company
Seagen Inc.
Sairopa B.V.
Merck Sharp & Dohme LLC
Virginia Commonwealth University
Eli Lilly and Company
Merck Sharp & Dohme LLC
Tempest Therapeutics
Merck Sharp & Dohme LLC
NuCana plc
Medicenna Therapeutics, Inc.
Yale University
Merck Sharp & Dohme LLC
Dana-Farber Cancer Institute
Yonsei University
Inspirna, Inc.
GV20 Therapeutics
Washington University School of Medicine
Carisma Therapeutics Inc
NextCure, Inc.
Five Prime Therapeutics, Inc.
Merck Sharp & Dohme LLC
Vincerx Pharma, Inc.
EDDC (Experimental Drug Development Centre), A*STAR Research Entities